NSD2 shows gain of function in blood cancers due to fusions to the IgH locus via t(4;14) translocations that cause its overexpression in multiple myeloma2, 3 or recurrent E1099K mutations that enhance its methyltransferase activity in lymphomas4, 5, 6. Here, NSD2 is linked to hematopoietic and lymphoid system neoplasm.